Defunct Company
Total Trials
3
As Lead Sponsor
1
As Collaborator
2
Total Enrollment
249
NCT03512340
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 13, 2018
Completion: Sep 29, 2020
NCT04336098
Study of SRF617 in Patients With Advanced Solid Tumors
Role: Collaborator
Start: Mar 16, 2020
Completion: Aug 25, 2023
NCT05177770
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Phase: Phase 2
Start: Jan 17, 2022
Completion: Apr 5, 2023